The first strong outlook factor for IHE is its inclusion of Eli Lilly at almost 27% weight. The pharmaceutical company has seen tremendous growth due to Mounjaro, approved by the FDA in 2022, and ...
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results